Zacks: Brokerages Expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Will Announce Quarterly Sales of $12.80 Million

Brokerages expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to announce sales of $12.80 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for BioCryst Pharmaceuticals’ earnings, with the highest sales estimate coming in at $21.81 million and the lowest estimate coming in at $7.40 million. BioCryst Pharmaceuticals reported sales of $4.82 million during the same quarter last year, which indicates a positive year over year growth rate of 165.6%. The business is scheduled to announce its next quarterly earnings results before the market opens on Thursday, May 6th.

According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full-year sales of $73.63 million for the current financial year, with estimates ranging from $57.83 million to $84.45 million. For the next financial year, analysts expect that the firm will report sales of $152.53 million, with estimates ranging from $124.82 million to $203.82 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, February 24th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.09). BioCryst Pharmaceuticals had a negative return on equity of 328.70% and a negative net margin of 233.45%. The firm had revenue of $4.02 million during the quarter, compared to the consensus estimate of $14.72 million.

Several brokerages have weighed in on BCRX. Needham & Company LLC reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Thursday, April 15th. JPMorgan Chase & Co. upped their target price on BioCryst Pharmaceuticals from $10.00 to $15.00 and gave the company an “overweight” rating in a research note on Wednesday, March 17th. Cowen started coverage on BioCryst Pharmaceuticals in a report on Monday, March 1st. They issued an “outperform” rating and a $16.00 price target for the company. Zacks Investment Research upgraded BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 15th. Finally, HC Wainwright boosted their price target on BioCryst Pharmaceuticals from $14.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, March 30th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $11.55.

Shares of NASDAQ BCRX opened at $11.01 on Wednesday. The business’s 50 day moving average is $11.22 and its two-hundred day moving average is $8.52. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.45 and a quick ratio of 1.40. BioCryst Pharmaceuticals has a 1-year low of $3.30 and a 1-year high of $14.24. The stock has a market capitalization of $1.96 billion, a P/E ratio of -14.49 and a beta of 3.03.

Several hedge funds have recently modified their holdings of BCRX. FMR LLC increased its position in shares of BioCryst Pharmaceuticals by 15.9% during the first quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company’s stock worth $28,229,000 after purchasing an additional 475,989 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in BioCryst Pharmaceuticals by 1,559.3% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 11,615 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 10,915 shares during the period. Schonfeld Strategic Advisors LLC grew its position in BioCryst Pharmaceuticals by 44.4% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 241,411 shares of the biotechnology company’s stock worth $830,000 after purchasing an additional 74,183 shares during the period. North Star Investment Management Corp. grew its position in BioCryst Pharmaceuticals by 71.5% during the 4th quarter. North Star Investment Management Corp. now owns 300,190 shares of the biotechnology company’s stock worth $2,236,000 after purchasing an additional 125,190 shares during the period. Finally, Sowell Financial Services LLC grew its position in BioCryst Pharmaceuticals by 39.8% during the 4th quarter. Sowell Financial Services LLC now owns 11,695 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 3,328 shares during the period. 72.00% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Recommended Story: How Do Front-End Loads Impact an Investment?

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.